Detalhe da pesquisa
1.
Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.
Clin Infect Dis
; 76(10): 1832-1840, 2023 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36645792
2.
Pharmacokinetics of Single-Dose Versus Double-Dose Dolutegravir After Switching From a Failing Efavirenz-Based Regimen.
J Acquir Immune Defic Syndr
; 96(1): 85-91, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38372621
3.
Virologic outcomes with tenofovir-lamivudine-dolutegravir in adults failing PI-based second-line ART.
South Afr J HIV Med
; 25(1): 1567, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38725705
4.
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.
Lancet HIV
; 10(7): e433-e441, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37230101
5.
Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.
J Acquir Immune Defic Syndr
; 92(5): 422-429, 2023 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706364